Immunome Inc. (IMNM) Stock
4 of the hedge funds AlphaScala tracks reported IMNM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $10.61M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own IMNM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 501K | $10.61M | -66% |
| Renaissance Technologies Jim Simons (founder) | 251K | $5.32M | +264% |
| Citadel Ken Griffin | 224K | $4.75M | +179% |
| Blackstone | 11K | $224.0K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Immunome Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 11, 26 | Higgins Jack | Chief Scientific Officer | SELL | 13.2K | $334K |
| Aug 12, 26 | Barchas Isaac | Director | SELL | 11.0K | $301K |
| Aug 11, 26 | Barchas Isaac | Director | SELL | 62.3K | $1.6M |
| Aug 10, 26 | Barchas Isaac | Director | SELL | 10.1K | $264K |
| Aug 7, 26 | Barchas Isaac | Director | SELL | 15.2K | $397K |
| Aug 6, 26 | Barchas Isaac | Director | SELL | 20.8K | $543K |
| Aug 4, 26 | Horn Kinney | CHIEF BUSINESS OFFICER | SELL | 90.6K | $2.3M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →IMNM price chart
Powered by TradingViewWhat does Immunome Inc. do?
Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector. The primary focus of the company is to advance immunotherapy-based cancer treatments through its proprietary discovery engine that harnesses the immune system's natural capabilities. Immunome’s approach involves leveraging its unique antigen technology to identify novel targets and develop therapeutic antibodies, aimed at enabling the body's immune response to recognize and combat cancer more effectively. This cutting-edge focus places Immunome Inc. squarely at the forefront of the biologics market, with potential applications spanning various oncology therapies. Since its inception, the company has continually explored partnerships with academic institutions and other biotech firms, enhancing collaborative efforts to propel novel findings from the laboratory to clinical trials. Immunome’s efforts contribute significantly to the pharmaceutical and healthcare industries, underscoring the growing importance of targeted therapies and personalized medicine in addressing complex medical challenges. Based in Exton, Pennsylvania, Immunome Inc. represents a key player in translating breakthrough immunological insights into tangible healthcare solutions, emphasizing robust scientific innovation in combating one of the world's most persistent health issues.